TipRanks (Fri, 11-Sep 4:20 AM ET)
Pacific Biosciences (PACB) Has a New Rating from UBS
TipRanks (Wed, 9-Sep 6:46 AM ET)
PacBio to Participate in the Morgan Stanley 24?? Annual Global Healthcare Conference
Globe Newswire (Thu, 3-Sep 4:05 PM ET)
PacBio Appoints Mark Van Oene as President and Chief Executive Officer
Globe Newswire (Wed, 5-Aug 4:08 PM ET)
PacBio Announces Second Quarter 2026 Financial Results
Globe Newswire (Wed, 5-Aug 4:05 PM ET)
Globe Newswire (Wed, 5-Aug 9:05 AM ET)
PacBio to Participate in the Canaccord Genuity 46th Annual Growth Conference
Globe Newswire (Tue, 28-Jul 4:05 PM ET)
PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026
Globe Newswire (Wed, 15-Jul 4:05 PM ET)
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
Pacific Biosciences Of California trades on the NASDAQ stock market under the symbol PACB.
As of September 11, 2026, PACB stock price climbed to $1.28 with 671,464 million shares trading.
PACB has a beta of 1.17, meaning it tends to be more sensitive to market movements. PACB has a correlation of 0.02 to the broad based SPY ETF.
PACB has a market cap of $397.86 million. This is considered a Small Cap stock.
Last quarter Pacific Biosciences Of California reported $39 million in Revenue and -$.14 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.01.
In the last 3 years, PACB traded as high as $11.96 and as low as $.85.
The top ETF exchange traded funds that PACB belongs to (by Net Assets): ARKE, ARKK, ARKG, VTI, VXF.
PACB has underperformed the market in the last year with a price return of +4.9% while the SPY ETF gained +18.4%. PACB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -6.6% and -17.4%, respectively, while the SPY returned +5.7% and -0.8%, respectively.
PACB support price is $1.20 and resistance is $1.34 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PACB shares will trade within this expected range on the day.
